- Report
- September 2024
- 183 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- July 2024
- 150 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- November 2023
- 68 Pages
Global
From €2804EUR$2,950USD£2,356GBP
- Report
- August 2023
- 120 Pages
Global
From €4421EUR$4,650USD£3,714GBP
- Report
- July 2023
- 114 Pages
Global
From €4421EUR$4,650USD£3,714GBP
- Report
- October 2023
- 190 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- February 2020
- 120 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- January 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- November 2021
- 120 Pages
Global
€2852EUR$3,000USD£2,396GBP
- Report
- July 2023
- 113 Pages
Global
From €3500EUR$3,944USD£3,043GBP
The Artificial Blood market is a subset of the larger Biomaterials market. Artificial Blood is a synthetic, lab-created product designed to replace or supplement natural blood in medical treatments. It is typically used in transfusions, and can be used to treat a variety of conditions, including anemia, trauma, and surgery. Artificial Blood is typically composed of hemoglobin, a protein found in red blood cells, and other components such as lipids, carbohydrates, and electrolytes.
The Artificial Blood market is driven by the increasing demand for blood transfusions, as well as the need for safer and more effective alternatives to natural blood. Additionally, the development of new technologies and materials has enabled the production of more efficient and cost-effective Artificial Blood products.
Notable companies in the Artificial Blood market include Hemopure, Hemosol, Baxter International, and Northfield Laboratories. Show Less Read more